(E)-2-(3,4-dimethoxyphenyl)-4-(pyridin-3-ylmethylene)oxazol-5(4H)-one

(E)-2-(3,4-dimethoxyphenyl)-4-(pyridin-3-ylmethylene)oxazol-5(4H)-one Suppliers list
Company Name: Shanghai YuanYe Biotechnology Co., Ltd.  
Tel: 15026964105
Email: 2881489226@qq.com
Company Name: Shanghai Chaolan Chemical Technology Center  
Tel: QQ:65489617 13301690235
Email: Sales@ATKchemical.com
Company Name: TargetMol Chemicals Inc.  
Tel: +1-781-999-5354; +1-00000000000
Email: marketing@targetmol.com
Company Name: Jingmo (Xiamen) Biotechnology Co., Ltd  
Tel: 13621943973; 13621943973
Email: sales@jamxmpharmatech.com
Company Name: Jinan Jiuli Biotechnology Co. , Ltd.  
Tel: 15865264761
Email: 486064515@qq.com

(E)-2-(3,4-dimethoxyphenyl)-4-(pyridin-3-ylmethylene)oxazol-5(4H)-one manufacturers

  • DAPK-IN-2
  • DAPK-IN-2 pictures
  • $58.00
  • 2026-08-08
  • CAS:304000-05-3
  • Purity: 98.26%
  • Supply Ability: 10g
(E)-2-(3,4-dimethoxyphenyl)-4-(pyridin-3-ylmethylene)oxazol-5(4H)-one Basic information
Product Name:(E)-2-(3,4-dimethoxyphenyl)-4-(pyridin-3-ylmethylene)oxazol-5(4H)-one
Synonyms:(E)-2-(3,4-dimethoxyphenyl)-4-(pyridin-3-ylmethylene)oxazol-5(4H)-one;WAY-380496;2-(3,4-Dimethoxyphenyl)-4-(3-pyridinylmethylene)-5(4H)-oxazolone;5(4H)-Oxazolone, 2-(3,4-dimethoxyphenyl)-4-(3-pyridinylmethylene)-;DAPK-IN-2;2-(3,4-Dimethoxyphenyl)-4-(pyridin-3-ylmethylene)oxazol-5(4H)-one;2-(3,4-dimethoxyphenyl)-4-[(pyridin-3-yl)methylidene]-4,5-dihydro-1,3-oxazol-5-one
CAS:304000-05-3
MF:C17H14N2O4
MW:310.3
EINECS:
Product Categories:
Mol File:304000-05-3.mol
(E)-2-(3,4-dimethoxyphenyl)-4-(pyridin-3-ylmethylene)oxazol-5(4H)-one Structure
(E)-2-(3,4-dimethoxyphenyl)-4-(pyridin-3-ylmethylene)oxazol-5(4H)-one Chemical Properties
Boiling point 460.9±55.0 °C(Predicted)
density 1.26±0.1 g/cm3(Predicted)
pka3.44±0.12(Predicted)
form Solid
color Light yellow to yellow
Safety Information
MSDS Information
(E)-2-(3,4-dimethoxyphenyl)-4-(pyridin-3-ylmethylene)oxazol-5(4H)-one Usage And Synthesis
UsesDAPK-IN-2 is a DAPK inhibitor. DAPK-IN-2 can be used for the research of cerebral infarction and ischemic diseases[1].
References[1] Okamoto M, et al. Structure-activity relationship of novel DAPK inhibitors identified by structure-based virtual screening. Bioorg Med Chem. 2010;18(7):2728-2734. DOI:10.1016/j.bmc.2010.02.018
(E)-2-(3,4-dimethoxyphenyl)-4-(pyridin-3-ylmethylene)oxazol-5(4H)-one Preparation Products And Raw materials
Tag:(E)-2-(3,4-dimethoxyphenyl)-4-(pyridin-3-ylmethylene)oxazol-5(4H)-one(304000-05-3) Related Product Information
4-[3,4-bis(benzyloxy)benzylidene]-2-(4-chlorophenyl)-1,3-oxazol-5(4H)-one (4Z)-2-(4-bromophenyl)-4-[(2,3,4-trimethoxyphenyl)methylidene]-1,3-oxazol-5-one 4-{3-bromo-5-ethoxy-4-[2-(4-methylphenoxy)ethoxy]benzylidene}-2-phenyl-1,3-oxazol-5(4H)-one 4-{4-[(4-methylbenzyl)oxy]benzylidene}-2-(4-methylphenyl)-1,3-oxazol-5(4H)-one 4-[3,4-bis(benzyloxy)benzylidene]-2-(3-iodophenyl)-1,3-oxazol-5(4H)-one 4-(2-bromo-4,5-diethoxybenzylidene)-2-phenyl-1,3-oxazol-5(4H)-one